AlloVir (NASDAQ:ALVR) Stock Falls 0.3% – What’s Next?

Shares of AlloVir, Inc. (NASDAQ:ALVR – Get Free Report) dropped 0.3% during mid-day trading on Thursday. The company traded as low as $2.75 and last traded at $2.89. Approximately 102,557 shares changed hands during trading, an increase of 554% from the average daily volume of 15,685 shares. The stock had previously closed at $2.90.

AlloVir Trading Down 0.3%

The company has a 50 day simple moving average of $3.69 and a 200-day simple moving average of $4.72. The stock has a market cap of $14.57 million, a price-to-earnings ratio of -0.14 and a beta of 0.63.

AlloVir Company Profile

(Get Free Report)

AlloVir, Inc was a biotechnology company focused on developing allogeneic, virus-specific T-cell therapies for people whose immune systems are compromised, including recipients of organ or stem-cell transplants. Its research sought to address serious viral infections that can occur when patients cannot mount an effective immune response.

The company’s leading investigational product was posoleucel, also known as ALVR105, an “off-the-shelf” multivirus-specific T-cell therapy designed to target several viruses, including cytomegalovirus, Epstein-Barr virus, adenovirus, BK virus and human herpesvirus 6.

See Also

• Five stocks we like better than AlloVir
• Everyone in AI Is Quietly Copying Palantir’s Playbook
• Advanced Micro Devices Is Spending $8.2 Billion to Learn What AI Needs Next
• JPMorgan Bets on Genius Sports as the Market Loses Patience
• Apple’s $5.7 Billion Patent Verdict Raises a Bigger Royalty Question